- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07877727
Empowering the Clinical Management of BMFs Through a Biological and Genetically Driven Pediatric and Adult National Network (2023-12377081)
Potenziare la Gestione Clinica Delle CMF Attraverso Una Rete Nazionale Pediatrica e Dell'Adulto Basata su Dati Biologici e Genetici / Empowering the Clinical Management of BMFs Through a Biological and Genetically Driven Pediatric and Adult National Network
A non-profit, translational, prospective and retrospective study.
Patients will be enrolled according to the procedures described in the protocol, and samples will be processed and analyzed as specified in the protocol.
Since constitutional bone marrow failure syndromes (CMF) are rare genetic disorders characterized by a variable and incompletely defined clinical phenotype, a partially unknown genetic etiology, and pathogenetic mechanisms that are only partly understood, the investigators hypothesize that a number of patients currently diagnosed with idiopathic acquired aplastic anemia (AAA) or idiopathic single-lineage/multilineage bone marrow failure (BMF) may have been misdiagnosed and may actually have an underlying CMF.
Therefore, the investigators' primary objective is to identify CMF underlying BMF and vice versa, by defining well-characterized patient cohorts based on clinical and family history, clinical manifestations, and immunological findings; identifying disease-specific parameters and biomarkers; and providing disease-specific guidelines to facilitate early diagnosis and, consequently, enable timely and appropriate treatment.
In this context, the use of appropriate artificial intelligence (AI) tools is likely to improve the diagnostic accuracy of this approach.
Studienübersicht
Status
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Carlo Dufour
- Telefonnummer: +3901056363528
- E-Mail: segrematologia@gaslini.org
Studienorte
-
-
-
Avellino, Italien
- Rekrutierung
- AORN San Giuseppe Moscati Hematology and bone marrow Transplant Unit
-
Kontakt:
- Antonio Maria Risitano
- Telefonnummer: +393475786759
- E-Mail: amrisita@unina.it
-
Genova, Italien
- Rekrutierung
- IRCCS Istituto Giannina Gaslini
-
Kontakt:
- Carlo Dufour
- Telefonnummer: +3901056363528
- E-Mail: segrematologia@gaslini.org
-
Naples, Italien
- Rekrutierung
- Azienza Ospedaliera di Rilievo Nazionale Santobono Pausilipon Dipartimento di oncologia, ematologia e terapie cellulari
-
Kontakt:
- Giuseppe Menna
- Telefonnummer: +393485171510
- E-Mail: giumenna56@libero.it
-
Verona, Italien
- Noch keine Rekrutierung
- Università degli Studi di Verona Department of Engineering for Innovation Medicine
-
Kontakt:
- Anna Savoia
- Telefonnummer: +393284695593
- E-Mail: Anna.savoia@univr.it
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
All patients with Fanconi anemia (FA), dyskeratosis congenita (DC) and other telomere biology disorders (TBD), congenital neutropenia (CN), primary immune regulatory disorders (PIRD), congenital amegakaryocytic thrombocytopenia (CAMT), and acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH)
Beschreibung
Inclusion Criteria:
- Patients diagnosed with Fanconi anemia (FA), dyskeratosis congenita (DC) and other telomere biology disorders (TBD), congenital neutropenia (CN), primary immune regulatory disorders (PIRD), congenital amegakaryocytic thrombocytopenia (CAMT), and acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH).
- Signed informed consent and/or assent obtained from the participant and/or their parents or legal guardians, as applicable.
Exclusion Criteria:
- Absence of signed informed consent and/or assent from the participant and/or their parents or legal guardians
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
Fanconi anemia (FA)
Fanconi anemia (FA) |
|
Dyskeratosis congenita (DC) e altri telomere biology disorders (TBD)
Dyskeratosis congenita (DC) e altri telomere biology disorders (TBD) |
|
Congenital neutropenia (CN)
Congenital neutropenia (CN) |
|
Primary immune regulatory disorders (PIRD)
Primary immune regulatory disorders (PIRD) |
|
Congenital amegakaryocytic thrombocytopenia (CAMT)
Congenital amegakaryocytic thrombocytopenia (CAMT) |
|
Acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH)
Acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH) |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Early Diagnosis and Molecular Characterization of CMF and AAA
Zeitfenster: Within the 24-month project period
|
To improve the early diagnosis of constitutional bone marrow failure syndromes (CMF) and acquired aplastic anemia (AAA) through the integration of clinical, laboratory, immunological, and genetic data. At least 50 newly enrolled patients will be evaluated prospectively over the first 21 months, alongside approximately 200 previously referred patients analyzed retrospectively using artificial intelligence (AI). The diagnostic work-up will include the implementation of additional tests, such as telomere length assessment by flow-FISH, serum thrombopoietin measurement, and immunophenotyping by flow cytometry. Whole-genome sequencing and functional studies will be used to identify disease-causing variants, copy number variations (CNVs), and clarify variants of uncertain significance (VUS). Early and accurate diagnosis will support appropriate targeted treatment, genetic counseling, surveillance for bone marrow failure and malignancies, and identification of suitable related donors. |
Within the 24-month project period
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Störungen des Knochenmarkversagens
- Genetische Krankheiten, angeboren
- Stoffwechselerkrankungen
- Säugling, Neugeborenes, Krankheiten
- Hämatologische Erkrankungen
- Hautkrankheiten
- Angeborene Anomalien
- Erkrankungen des Knochenmarks
- Anämie, hämolytisch
- Anämie
- Hautkrankheiten, genetisch
- Genetische Krankheiten, X-gebunden
- Hautanomalien
- Myelodysplastische Syndrome
- DNA-Reparatur-Mangel-Störungen
- Anämie, hypoplastisch, angeboren
- Anämie, aplastisch
- Angeborene, erbliche und neonatale Krankheiten und Anomalien
- Ernährungs- und Stoffwechselerkrankungen
- Haut- und Bindegewebserkrankungen
- Hämische und lymphatische Krankheiten
- Angeborene Knochenmarkinsuffizienzsyndrome
- Hämoglobinurie, paroxysmal
- Fanconi-Anämie
- Dyskeratosis congenita
- Angeborene amegakaryozytische Thrombozytopenie
- Neutropenie, schwere angeborene, autosomal rezessive 3
Andere Studien-ID-Nummern
- PNRR-MR1-2023-12377081 (13958)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .